Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

View all →   RSSRecent Releases
May 16, 2018 Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
May 10, 2018 Form 10-Q View HTML View PDF 430.4 KB Add to Briefcase
Mar 7, 2018 Form 10-K View HTML View PDF 1.6 MB Add to Briefcase
Add to Briefcase = add file to Briefcase